CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 170 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 1.0 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642651
NCT04642651Phase 4Completed
CompareCT.gov

Impacts of Dexmedetomidine as an Adjuvant for Femoral Nerve Block on Functional Recovery in Aged Patients After Total Knee Arthroplasty: a Randomized, Double-blinded, Controlled Trial

Peking University First Hospital·interventional·Posted Nov 24, 2020·Updated Apr 20, 2022

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine and Placebo for Elderly and 4 related conditions. Completed, enrolled 170 participants across 2 sites.

Detailed Summary

Femoral nerve block (FNB) is a first-line analgesic technique for multimodal analgesia after total knee arthroplasty (TKA). Recent studies and meta-analysis indicate that dexmedetomidine combined with local anesthetics for FNB can prolong the analgesic duration, improve the analgesic efficacy, inhibit local inflammatory response, and reduce narcotic consumption. The investigators hypothesize that dexmedetomidine combined with ropivacaine for FNB can also improve functional recovery in aged patients after TKA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElderly, Total Knee Arthroplasty, Femoral Nerve Block, Dexmedetomidine, Functional Outcome
CountriesChina
CollaboratorsBeijing Jishuitan Hospital

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedNov 24, 2020
Enrollment StartNov 25, 2020
Primary CompletionNov 22, 2021
Study CompletionFeb 25, 2022
TodayJul 1, 2026
Enrollment to primary: 12 monthsPosted 5.6 years ago

Interventions

Dexmedetomidinedrug

Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.

Placebodrug

Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.